Why carry out this study?
|
Patients with plaque psoriasis and comorbidities, such as obesity, or those who have received prior biologic treatment, often have difficulty achieving high levels of efficacy using many of the current biologic therapies for moderate-to-severe psoriasis. |
Efficacious therapies are needed to provide adequate clinical benefit across a variety of patients, regardless of patient demographics and disease characteristics, including obesity, treatment history, and disease duration. |
This subanalysis of the IMMerge phase 3 clinical trial assessed risankizumab efficacy compared with secukinumab at week 52 across patient subgroups. Analyses included body weight, body mass index, prior biologic history, disease duration, and the durability of risankizumab efficacy at week 52. |
What was learned from the study?
|
Risankizumab showed greater efficacy compared with secukinumab, regardless of patient demographics and disease characteristics, and efficacy was maintained at week 52. |
Results from this subgroup analysis support risankizumab treatment for a variety of patients, including those who are difficult to treat. |
Introduction
Methods
Study Design and Treatment
Assessments
Efficacy
Safety
Statistical Analysis
Results
Patients
Characteristic | Risankizumab 150 mg (N = 164) | Secukinumab 300 mg (N = 163) |
---|---|---|
Age (years), mean (SD) | 47.3 (13.4) | 46.8 (14.9) |
Male, n (%) | 112 (68.3) | 101 (62.0) |
Race, n (%) | ||
White | 151 (92.1) | 144 (88.3) |
Black/African American | 6 (3.7) | 6 (3.7) |
Asian | 6 (3.7) | 11 (6.7) |
American Indian/Alaskan Native | 1 (0.6) | 0 |
Native Hawaiian/Pacific Islander | 0 | 2 (1.2) |
Hispanic or Latino, n (%) | 37 (22.6) | 34 (20.9) |
BMI, kg/m2, n (%) | ||
< 25 | 36 (22.0) | 37 (22.7) |
25 to < 30 | 52 (31.7) | 47 (28.8) |
≥ 30 | 76 (46.3) | 79 (48.5) |
Duration of plaque psoriasis, years, mean (SD) | 18.6 (12.6) | 17.4 (13.2) |
sPGA, n (%) | ||
Moderate (score of 3) | 140 (85.4) | 137 (84.0) |
Severe (score of 4) | 24 (14.6) | 25 (15.3) |
< Moderate (score of 3) or missing | 0 | 1 (0.6) |
BSA, mean (SD) | 23.8 (13.8) | 26.0 (16.1) |
Psoriatic arthritis, n (%) | ||
No | 137 (83.5) | 140 (85.9) |
Yes | 27 (16.5) | 23 (14.1) |
PASI, mean (SD) | 19.8 (6.3) | 20.1 (8.1) |
Prior systemic treatments for psoriasis, n (%) | ||
No | 102 (62.2) | 105 (64.4) |
Yes | 62 (37.8) | 58 (35.6) |